Billion To One

We are ONE team,
working towards ONE goal to

detect disease

ONE molecule at a time.

Closeup of BTO lab equipment and an animation showing a grid of letters A T C and G with the focus moving to different letters in the grid

One in a
Few Billion

There are three billion letters, three billion nucleotides that make up our genome. Our proprietary technology has the ability to detect and quantify disease at single base-pair resolution. Our name speaks to this unique technology, and we are focused on applying it to various disease states to help more patients.

Mission, Vision, Values

At the Forefront of
Disease Detection

woman working in a lab

Our proprietary Quantitative Counting Templates, or QCTs™, power our ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. Several common and severe recessive conditions screened for prenatally can be caused by single-base pair alterations.
Our QCT technology enables quantifying these tiny variations using cell-free DNA. We believe this quantification will open the door to exponential improvements in prenatal screening, liquid biopsy, and beyond.

Moving Prenatal Screening and Oncology Testing Forward

Prenatal closeup on pregnant woman's stomach with her hands lovingly held above and below her belly.

We assess fetal risk for recessive conditions and aneuploidies from maternal blood.
UNITY Screen™ includes a carrier screen as well as a single-gene (for recessive conditions) and aneuploidy NIPT and only requires a maternal blood draw at 10+ weeks to assess fetal risk. No paternal sample needed.

Explore Prenatal
Oncology gloved hand holding a test tube with blood

Northstar Select™ and Northstar Response™ are now available for commercial use.
Northstar Select™ helps determine the most appropriate first line therapy, and Northstar Response™ helps monitor if the therapy is working.

Explore Oncology

Coupling Careers with Great Culture

Three employees - a man and two women, one with bright scarlet hair - standing at a computer and working together in a Billion To One lab

“BillionToOne’s leadership values growth of the company’s employees and equality among peers.”

Three employees - a man and two women, one with bright scarlet hair - standing at a computer and working together in a Billion To One lab

“I love BillionToOne’s culture, everyone is so welcoming and always open to lend a helping hand.”

Three employees - a man and two women, one with bright scarlet hair - standing at a computer and working together in a Billion To One lab

“We have a very strong culture of cross-departmental teamwork. Everyone here cares about making an impact!”

Three employees - a man and two women, one with bright scarlet hair - standing at a computer and working together in a Billion To One lab

“I love being able to introduce the latest and greatest technology to Women’s Health providers that will improve their knowledge on each pregnancy and give babies the best shot at healthy beginnings!”

Coupling Careers with Great Culture

What unites our team and drives us forward is one goal of making molecular testing more accurate, efficient, and accessible to all. This special group of bright and talented people is improving healthcare. If this appeals to you, consider joining us.

Leading with Passion and Purpose

Co-founders Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and our team of engineers, scientists, and industry experts care deeply about every sample that comes into our lab.

Collage of three photos: headshots of the two founders and one of a man and woman at a whiteboard

News & Media

View All

Press Releases

Leading Molecular Diagnostics Company BillionToOne Raises $130 Million in Oversubscribed Series D Funding Over $1B+ Valuation

Read Article

Media Coverage

Oguzhan Atay recognized by Slice of Healthcare as a Top Leader in Digital Health

Read Article

General Information

With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay

Read Article

Media Coverage

ASCO24: BillionToOne unveils results from tumour profiling test comparison

Read Article

Media Coverage

GenomeWeb- BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test

Read Article

Media Coverage

BioWorld MedTech Interview- BillionToOne test reduces need for Rhogam in 40% of Rh-negative pregnancies

Read Article

Press Releases

BILLIONTOONE MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST

Read Article

Media Coverage

BillionToOne is recognized by Forbes as one of America’s Best Startup Employers for 2024!

Read Article

Press Releases

BILLIONTOONE ANNOUNCES ROSS TAYLOR AS CHIEF FINANCIAL OFFICER

Read Article

Press Releases

BillionToOne to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Read Article